Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL839371 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| SCHEMBL3095991 | 0.98 | CYP1A2 (0.48) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Hydrochloric Acid SCHEMBL28506360 | 0.95 | CYP1A2 (0.47) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| SCHEMBL301678 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL248532 | 0.88 | CYP1A2 (0.54) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Carbimide SCHEMBL8927383 | 0.88 | CYP1A2 (0.54) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Ethane SCHEMBL8026831 | 0.88 | CYP1A2 (0.54) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Ethane SCHEMBL2545448 | 0.86 | CYP1A2 (0.52) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Iodomethane SCHEMBL7521844 | 0.86 | CYP1A2 (0.52) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 | |
| Hydrochloric Acid SCHEMBL28296907 | 0.86 | CYP1A2 (0.52) | ALDH1A1TSHRCYP1A2CYP2D6DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119552107-A | Heteroaromatic amide CYP1B1 enzyme inhibitor, and preparation method and application thereof | 沈阳药科大学 | 2025-03-04 | — | — | CN | claimed |
| EP-0264797-A2 | Benzodiazepines assay, tracers, immunogens and antibodies | ABBOTT LABORATORIES (US) | 1988-04-27 | — | — | EP | claimed |
| WO-2023023531-A1 | ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-108078982-B | Use of proline derivatives in preparation of β -lactamase inhibitor | 天津大学 | 2020-02-07 | — | — | CN | disclosed |
| EP-2908856-B1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-02-20 | — | — | EP | disclosed |
| US-20180193336-A1 | SPRAY DRY FORMULATIONS | PULMOKINE, INC. | 2018-07-12 | — | — | US | disclosed |
| CN-103649053-B | Aminomethyl quinolone compounds | 霍夫曼-拉罗奇有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-105307498-A | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS INC | 2016-02-03 | — | — | CN | disclosed |
| EP-2908856-A1 | IMMUNOGENIC COMPOSITION | GlaxoSmithKline Biologicals S.A. (BE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2695877-B1 | Multi-functional monomer having a photocreative group, alignment film for LCD using the monomer, and LCD comprising the alignment film | LG CHEMICAL LTD (KR) | 2015-04-15 | — | — | EP | disclosed |
| EP-2504338-B1 | PYRIDINE-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| CN-1227564-A | Novel aromatic compounds substituted by ribose, preparation method and application as medicine thereof | HOECHST MARION ROUSSEL INC (FR) | 1999-09-01 | — | — | CN | disclosed |
| EP-0830371-A1 | IMIDAZO 1,5a]PYRIDINE DERIVED SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 1998-03-25 | — | — | EP | disclosed |
| US-5648124-A | Process for preparing magnetically responsive microparticles | SERADYN, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1996038470-A1 | IMIDAZO[1,5a]PYRIDINE DERIVED SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1996-12-05 | — | — | WO | disclosed |
| US-5532132-A | Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor | PRESIDENT AND FELLOWS OF HARVARD UNIVERSITY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5310927-A | Hypotensive agents; cognition activators; imidazolyl-2-aryl derivatives | GLAXO GROUP LIMITED (GB) | 1994-05-10 | — | — | US | disclosed |
| EP-0514193-A1 | N-linked imidazolyl-methyl benzofuran derivatives with antihypotensive activity | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
| US-H1018-H | Immunological method for the determination of free substances having hapten properties | HENNING BERLIN GMBH CHEMIE- UND PHARMAWERK (DE) | 1992-01-07 | — | — | US | disclosed |
| EP-0031722-B1 | WATER SOLUBLE GUANIDINE DERIVATIVES OF POLYENE MACROLIDES AND THE ESTERS THEREOF, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | A/S Dumex (Dumex Ltd.) (DK) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193336-A1 | SPRAY DRY FORMULATIONS | TEK, FLT1, KDR | ALDH1A1 3640/4885TSHR 586/4885CYP1A2 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.